All In Biotech

Drug Trial Radar · NCT06555796

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Actual

Start

Sep 23, 2024

Primary completion

Mar 13, 2027

Study completion May 7, 2029

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).

Conditions

  • Prostate Cancer
  • High-risk Biochemical Recurrence
  • High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
  • Non-metastatic Castration-sensitive Prostate Cancer

Interventions

  • XaluritamigDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
  2. Number of Participants Experiencing Treatment-related Adverse Events (TRAEs)Time frame: Up to approximately 2 years

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Minnesota Medical Center Fairview

    Minneapolis, Minnesota

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia

  • Cabrini Hospital

    Malvern, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.